Literature DB >> 25659268

Preparation and testing of a Haemophilus influenzae Type b/Hepatitis B surface antigen conjugate vaccine.

So Jung An1, Joo Sung Woo1, Myung Hwa Chae1, Sudeep Kothari1, Rodney Carbis2.   

Abstract

The majority of conjugate vaccines focus on inducing an antibody response to the polysaccharide antigen and the carrier protein is present primarily to induce a T-cell dependent response. In this study conjugates consisting of poly(ribosylribitolphosphate) (PRP) purified from Haemophilus influenzae Type b bound to Hepatitis B virus surface antigen (HBsAg) virus like particles were prepared with the aim of inducing an antibody response to not only the PRP but also the HBsAg. A conjugate consisting of PRP bound to HBsAg via an adipic acid dihydrazide (ADH) spacer induced strong IgG antibodies to both the PRP and HBsAg. When conjugation was performed without the ADH spacer the induction of an anti-PRP response was equivalent to that seen by conjugate with the ADH spacer, however, a negligible anti-HBsAg response was induced. For comparison, PRP was conjugated to diphtheria toxoid (DT) and Vi polysaccharide purified from Salmonella Typhi conjugated to HBsAg both using an ADH spacer. The PRPAH-DT conjugate induced strong anti-PRP and anti-DT responses, the Vi-AHHBsAg conjugate induced a good anti-HBsAg response but not as strong as that induced by the PRPAH-HBsAg conjugate. This study demonstrated that in mice it was possible to induce robust antibody responses to both polysaccharide and carrier protein provided the conjugate has certain physico-chemical properties. A PRPAH-HBsAg conjugate with the capacity to induce anti-PRP and anti-HBsAg responses could be incorporated into a multivalent pediatric vaccine and simplify formulation of such a vaccine.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Conjugate vaccine; Haemophilus influenzae Type b; Hepatitis B; Hepatitis B surface antigen (HBsAg); Polyribosylribitol phosphate (PRP)

Mesh:

Substances:

Year:  2015        PMID: 25659268     DOI: 10.1016/j.vaccine.2015.01.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.

Authors:  So Jung An; Puthupparampil V Scaria; Beth Chen; Emma Barnafo; Olga Muratova; Charles Anderson; Lynn Lambert; Myung Hwa Chae; Jae Seung Yang; Patrick E Duffy
Journal:  Vaccine       Date:  2018-04-20       Impact factor: 3.641

Review 2.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

Review 3.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873

4.  Rotavirus spike protein ΔVP8* as a novel carrier protein for conjugate vaccine platform with demonstrated antigenic potential for use as bivalent vaccine.

Authors:  Wook-Jin Park; Yeon-Kyung Yoon; Ji-Sun Park; Ruchirkumar Pansuriya; Yeong-Jae Seok; Ravi Ganapathy
Journal:  Sci Rep       Date:  2021-11-11       Impact factor: 4.379

5.  Elicitation of integrated immunity in mice by a novel pneumococcal polysaccharide vaccine conjugated with HBV surface antigen.

Authors:  Wen Qian; Zhen Huang; Yuqiu Chen; Jinling Yang; Lili Wang; Kai Wu; Min Chen; Nanping Chen; Yongzhong Duan; Jing Shi; Ying Zhang; Qihan Li
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.